Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial

Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial

Podrobná bibliografie
Hlavní autoři:	Mihaylova, B, Armitage, J, Briggs, A, Gray, A, Parish, S, Collins, R, Collaborati, H
Médium:	Conference item
Vydáno:	2005

Podobné jednotky

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
Autor: Mihaylova, B, a další
Vydáno: (2005)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
Autor: Mihaylova, B, a další
Vydáno: (2006)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
Autor: Emberson, J, a další
Vydáno: (2005)

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
Autor: Armitage, J, a další
Vydáno: (2009)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
Autor: Emberson, J, a další
Vydáno: (2005)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
Autor: Bulbulia, R, a další
Vydáno: (2011)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Autor: Heart Protection Study Collaborative Group
Vydáno: (2002)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
Autor: Collins, R, a další
Vydáno: (2002)

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].
Autor: Group, H
Vydáno: (2005)

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]
Vydáno: (2005-03-01)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
Autor: Emberson, JR, a další
Vydáno: (2007)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
Autor: Collins, R, a další
Vydáno: (2004)

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
Autor: Heart Protection Study Collaborative Group
Vydáno: (2007)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Autor: Collins, R, a další
Vydáno: (2003)

Economic evaluation of the Heart Protection Study
Autor: Briggs, A, a další
Vydáno: (2003)

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
Autor: Mihaylova, B, a další
Vydáno: (2009)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
Autor: Hopewell, J, a další
Vydáno: (2009)

Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group.
Autor: Keech, A, a další
Vydáno: (1996)

Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.
Autor: Harris, M, a další
Vydáno: (1995)

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
Autor: Armitage, J, a další
Vydáno: (2010)

The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
Autor: Kent, S, a další
Vydáno: (2016)

Regarding "Does simvastatin save lives; If so, when and in whom?" - Reply
Autor: Bulbulia, R, a další
Vydáno: (2008)

20536. COMPLICACIONES NEUROLÓGICAS PARENQUIMATOSAS EN LA ENFERMEDAD DE BEHÇET
Autor: E. Estrada Palma, a další
Vydáno: (2024-11-01)

Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality
Autor: Parish, S, a další
Vydáno: (2010)

C-reactive protein in the Heart Protection Study Reply
Autor: Emberson, J, a další
Vydáno: (2011)

Safety of long-term simvastatin discontinuation Reply
Autor: Bulbulia, R, a další
Vydáno: (2012)

Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
Autor: Mitropoulos, K, a další
Vydáno: (1997)

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
Autor: Hopewell, J, a další
Vydáno: (2013)

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration
Autor: Wardle, J, a další
Vydáno: (1996)

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
Autor: Hopewell, JC, a další
Vydáno: (2020)

Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study
Autor: Susan Ball, a další
Vydáno: (2019-10-01)

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group.
Autor: Wardle, J, a další
Vydáno: (1996)

RPK 536 - PERANCANGAN PENGANGKUTAN FEB 01.
Autor: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Vydáno: (2001)

RPK 536 – Transportation Planning - Jun 2013
Autor: PPPBP, Pusat Pengajian Perumahan Bangunan Dan Perancangan
Vydáno: (2013)

RPK 536 - PERANCANGAN PENGANGKUTAN APRIL 1993.
Autor: PPPB, Pusat Pengajian Perumahan Bangunan & Perancangan (School of Houusing, Building & Planning)
Vydáno: (1993)

RMK536 - PERANCANGAN PENGANKUTAN APRIL 1995
Autor: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Vydáno: (1995)

RPK536 - PERANCANGAN PENGANGKUTAN FEBRUARI 1998
Autor: PPPB, Pusat Pengajian Perumahan Dan Bangunan
Vydáno: (1998)

RPK 536 — Perancangan Pengangkutan - Februari 2000
Autor: PPPBP, Pusat Pengajian Perumahan Bangunan Dan Perancangan
Vydáno: (2000)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Autor: Baigent, C, a další
Vydáno: (2011)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Autor: Baigent, C, a další
Vydáno: (2011)